SHARE

Accelerator

EIT Health and Biogen launch ‘neurotechprize’

15th November 2021

We are pleased to announce the launch of the ‘neurotechprize’, alongside Biogen. This programme wll rapidly identify technological solutions to the growing challenge of Alzheimer’s disease. Teams and researchers can apply now to be considered to take part. Participants will work with experts to receive mentoring and funding to bring their ideas to patients and their families in the form of new products and services.  

Alzheimer’s disease (AD), the most common form of dementia, has become one of the most pressing health concerns of the 21st century and is now regarded as a public health crisis.1 In line with our ageing population, incidence of dementia is growing. Over 55 million people live with dementia worldwide, and forecasts project that this figure will rise to 78 million by 2030.2

While there is currently no cure for AD, early diagnosis and treatment can help to slow disease progression and manage symptoms. However, stigma remains a key barrier to diagnosis. Public health bodies and organisations across the world are working to improve diagnosis. Such improvements will require innovative solutions for the subsequent management of newly diagnosed patients.

Alzheimer’s, alongside cancer, is our next big challenge following COVID-19. The pandemic has shown us clearly what can be achieved when science is put in the driving seat, and collaboration and focus are the words of the day. We must now use those lessons and the momentum to solve the devastating diseases that have been affecting us for a long time but will affect us much more acutely in the near future. Our experience tells us that while there are many great healthcare ideas waiting to be unlocked, the real difficulty is finding the right people and environments to deliver them to the market quickly and effectively. Direct collaboration between EIT Health and Biogen will give us all of the ingredients to foster, grow and test ideas, and rapidly commercialise those that can have impact,” said Jan-Philipp Beck, CEO of EIT Health.

Over a period of 10 weeks, teams will undergo an intense mentoring and validation process facilitated by EIT Health and Biogen experts. Following the work, teams will pitch their idea to an independent panel of experts, consisting of leading neurologists, patient representatives and payors who will award €100,000 and €50,000 prizes to the two best solutions.

“Through targeted start-up-collaborations, Biogen’s ambition is to combine the best in neuroscience and technology in one state-of-the-art open innovation platform – Neurotech Labs. We are thrilled to join forces with EIT Health and, together, create value for patients which exceeds the sum of our parts,” said Dr. Wolfram Schmidt, Senior Vice President, General Manager of Biogen Germany.

Find out more about ‘neurotechprize’ and apply by 19th December 2021.

  1. Cdc.gov. 2021. [online] Available at: <https://www.cdc.gov/aging/aginginfo/pdfs/Module1-Alzheimers-Disease-Public-Health-Crisis.pdf?fbclid=IwAR0eNeGAmT-sgbf3F1RKKJw_9kgRAymDAa-xIkMZT0YVqtVQkpu5tSHmYFY> [Accessed 18 October 2021].

  2. Alzint.org. 2021. [online] Available at: <https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf> [Accessed 18 October 2021].

Annika Szabo Portela appointed MD EIT Health Scandinavia

Annika Szabo Portela appointed MD EIT Health Scandinavia

Meet EIT Health Scandinavia's new MD

Find out more

EIT Health-supported Limula raises €4.7M

EIT Health-supported Limula raises €4.7M

Find out more about the EIC Pathfinder grant

Find out more

42 start-ups through to Catapult 2022-23 semifinals

42 start-ups through to Catapult 2022-23 semifinals

Discover the promising start-ups chosen

Find out more